NCT04700449 - A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

February 23, 2022

Study Completion Date

November 10, 2022

Conditions

Moderate to Severe Ulcerative Colitis

Interventions

DRUG

Double-Blind 0.2mg CBP-307

0.2 mg capsule oral administration

DRUG

Double-Blind Placebo

Placebo capsule oral administration

DRUG

Open-label CBP-307

0.2 mg capsule oral administration

DRUG

Double-Blind 0.1mg CBP-307

0.1 mg capsule oral administration

Trial Locations (66)

1135

Connect Investigative Site 2205, Kyiv

8173

Connect Investigative Site 2220, Kyiv

21021

Connect Investigative Site 2209, Vinnytsia

30309

Connect Investigative Site 2307, Atlanta

32803

Connect Investigative Site 2302, Orlando

32810

Connect Investigative Site 2304, Orlando

32819

Connect Investigative Site 2306, Orlando

33016

Connect Investigative Site 2314, Hialeah

33032

Connect Investigative Site 2309, Homestead

33126

Connect Investigative Site 2318, Miami

34741

Connect Investigative Site 2320, Kissimmee

45219

Connect Investigative Site 2315, Cincinnati

49005

Connect Investigative Site 2211, Dnipro

61037

Connect Investigative Site 2202, Kharkiv

61124

Connect Investigative Site 2208, Kharkiv

69035

Connect Investigative Site 2214, Zaporizhzhia

73102

Connect Investigative Site 2321, Oklahoma City

74800

Connect Investigative Site 2151, Karachi

75270

Connect Investigative Site 2152, Karachi

76018

Connect Investigative Site 2217, Ivano-Frankivsk

78229

Connect Investigative Site 2319, San Antonio

79005

Connect Investigative Site 2215, Lviv

79010

Connect Investigative Site 2216, Lviv

85018

Connect Investigative Site 2316, Phoenix

88000

Connect Investigative Site 2218, Uzhhorod

90212

Connect Investigative Site 2311, Cypress

91345

Connect Investigative Site 2308, Mission Hills

100050

Connect Investigative Site 2008, Beijing

100730

Connect Investigative Site 2001, Beijing

116027

Connect Investigative Site 2025, Dalian

117004

Connect Investigative Site 2040, Shenyang

130021

Connect Investigative Site 2015, Jilin

168600

Connect Investigative Site 2030, Nanning

200025

Connect Investigative Site 2011, Shanghai

200040

Connect Investigative Site 2007, Shanghai

200065

Connect Investigative Site 2019, Shanghai

200080

Connect Investigative Site 2035, Shanghai

200433

Connect Investigative Site 2038, Shanghai

210002

Connect Investigative Site 2027, Nanjing

210006

Connect Investigative Site 2031, Nanjing

210036

Connect Investigative Site 2023, Nanjing

215004

Connect Investigative Site 2033, Suzhou

230001

Connect Investigative Site 2018, Hefei

230022

Connect Investigative Site 2004, Hefei

250012

Connect Investigative Site 2028, Jinan

266000

Connect Investigative Site 2024, Qingdao

310003

Connect Investigative Site 2047, Hangzhou

310009

Connect Investigative Site 2032, Hangzhou

325027

Connect Investigative Site 2045, Wenzhou

330006

Connect Investigative Site 2046, Nanchang

350001

Connect Investigative Site 2006, Fuzhou

361004

Connect Investigative Site 2012, Xiamen

400037

Connect Investigative Site 2043, Chongqing

430022

Connect Investigative Site 2016, Wuhan

430030

Connect Investigative Site 2005, Wuhan

450052

Connect Investigative Site 2022, Zhengzhou

510120

Connect Investigative Site 2003, Guangzhou

510655

Connect Investigative Site 2009, Guangzhou

518035

Connect Investigative Site 2017, Shenzhen

518053

Connect Investigative Site 2021, Shenzhen

570311

Connect Investigative Site 2034, Haikou

610041

Connect Investigative Site 2013, Chengdu

050000

Connect Investigative Site 2026, Shijiazhuang

050011

Connect Investigative Site 2041, Shijiazhuang

Unknown

Connect Investigative Site 2044, Jinan

030001

Connect Investigative Site 2020, Taiyuan